A subgroup analysis in this study, using an eGFR threshold of 45 mL/min/1.73 m2, showed that SGLT2 inhibitors were more effective in reducing adverse events in CKD patients with an eGFR greater than 45 mL/min/1.73 m2 compared to those with lower eGFR values. The gene discussed is SLC5A2; the disease is chronic kidney disease.